Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03929250 · ClinicalTrials.gov registry record · Early Phase 1
Pharmacokinetics of Centella Asiatica in the Elderly
A Early Phase 1 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT03929250 is a Early Phase 1 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 8 participants.
The verdict
NCT03929250, a Early Phase 1 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study will measure the oral bioavailability and pharmacokinetics of known bioactive compounds from a standardized Centella asiatica water extract (CAW) product (CAP) in cognitively healthy elders.
Interventions
- DRUG 2g Centella asiatica water extract product
- DRUG 4g Centella asiatica water extract product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-07-05 |
| Est. Completion | 2024-01-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03929250
The ClinicalTrials.gov registry entry for NCT03929250 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 2g Centella asiatica water extract product is the first listed.
NCT03929250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03929250 about?
NCT03929250 is a clinical study titled "Pharmacokinetics of Centella Asiatica in the Elderly". This study will measure the oral bioavailability and pharmacokinetics of known bioactive compounds from a standardized Centella asiatica water extract (CAW) product (CAP) in cognitively healthy elders.
What is the current status of trial NCT03929250?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2019-07-05. Estimated completion is 2024-01-03.
What interventions are being tested in trial NCT03929250?
The interventions under investigation include: 2g Centella asiatica water extract product (DRUG), 4g Centella asiatica water extract product (DRUG).
Who is sponsoring clinical trial NCT03929250?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.